Lung Cancer 80 Suppl. 1 (2013) S67

Lung Cancer

journa l homepage: www.e lsev ier .com/ locate / lungcan

Contents lists available at SciVerse ScienceDirect

Drug index

Afatinib, S30 (65O)

Bevacizumab, S11 (26PD), S37 (85P)

Carboplatin, S20 (47P), S25 (55P), S31 (67O), S36 (81P), S55(125P)

Cisplatin, S25 (55P), S27 (60P), S28 (63P), S31 (67O), S36 (82P),S37 (84P, 85P), S38 (86P), S40 (93P)

Crizotinib, S2 (3P), S13 (31P)

Dacomitinib, S39 (92P)Docetaxel, S28 (63P), S32 (71PD), S37 (85P), S39 (90P), S40 (93P)

EGFR-TKI, S12 (27P), S30 (65O), S32 (71PD), S33 (73P), S35 (77P),S39 (91P)

Enobosarm, S32 (70PD)Erlotinib, S30 (65O), S32 (71PD), S33 (73P), S35 (79P), S39 (90P,

91P)Etoposide, S25 (55P), S36 (81P), S49 (115P)

Foretinib, S11 (26PD)

Gefitinib, S12 (27P), S30 (65O), S31 (68O), S32 (71PD), S36 (81P),S39 (91P, 92P)

Gemcitabine, S20 (47P), S37 (84P), S40 (93P)

Lanreotide, S20 (47P)

Paclitaxel, S25 (55P), S36 (81P)Pemetrexed, S34 (75P, 76P)

Tyrosine kinase inhibitors, S2 (5P), S12 (27P), S32 (69O), S33(73P)

Vintafolide, S16 (36O)

Zoledronic acid, S39 (91P)

*Page numbers for abstracts are followed by the abstract number(s) in parentheses.